Your Questions, Answered

We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.

Filter by topic:

The Eversense® CGM system has not been tested in patients receiving radiation treatment. If your HCP has questions about your Eversense® CGM, while undergoing medical treatments, we can connect them with a member of our clinical team to discuss their questions.  If you have any concerns and/or questions about the Eversense® 365 CGM System, we would ask you to contact our Customer Service Team at: eversense.us@ascensia.com or call us at 1-844-736-7348.  

DO NOT insert your infusion set within 4 inches (10.16 cm) of the sensor site. If the insulin delivery site is within 4 inches (10.16 cm) of the sensor site, it may interfere with sensor glucose readings and can cause inaccurate glucose readings.

X-ray, CT Scan:

DO NOT wear the smart transmitter during medical x-rays or computed tomography (CT) scans. To avoid interference with results, remove the smart transmitter before undergoing medical x-ray or CT scans. Make sure your health care professional knows about your smart transmitter.

Lithotripsy (Therapeutic Ultrasound) – The use of lithotripsy is not recommended for people who have an inserted sensor because the effects are unknown. DO NOT use lithotripsy near the sensor.

Diathermy:

DO NOT use diathermy on people who have an inserted sensor. Energy from the diathermy can transfer through the sensor and cause tissue damage in the insertion area.

Electrocautery:

The use of electrocautery near the inserted sensor may damage the device. DO NOT use electrocautery near the sensor.

The Eversense® 365 CGM System has not been tested in the following populations: women who are pregnant or nursing, people under the age of 18, critically ill or hospitalized patients, people receiving immunosuppressant therapy, chemotherapy or anti-coagulant therapy, those with another active implantable device, e.g., an implantable defibrillator (passive implants are allowed, e.g., cardiac stents), those with known allergies to or using systemic glucocorticoids (excluding topical, optical or nasal, but including inhaled).

The system’s accuracy hasn’t been tested in these populations, and sensor glucose readings may be inaccurate, resulting in missing a severe low or high glucose event.

It is safe for you to wear your sensor and smart transmitter when you go through metal detectors at airports. While flying, the smart transmitter performs similar to any other Bluetooth® device. Be sure to follow the specific safety guidelines mandated by the airline.

Still have questions?

The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.

For important safety information, see bit.ly/eversensesafety

Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.


Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

 

MKT-001692 Rev 1